一种丙酰胺衍生物在制备治疗神经系统疾病药物中的应用
By using N-[(6-methoxy-1H-benzimidazol-2-yl)methyl]-3-(pyridin-3-yl)propionamide derivatives to inhibit the overactivation of NMDA receptors, the problem of existing drugs interfering with normal nerve function was solved, achieving precise neuroprotection under pathological conditions and showing neuroprotective efficacy comparable to MK-801.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- LUDONG UNIVERSITY
- Filing Date
- 2026-03-13
- Publication Date
- 2026-07-17
AI Technical Summary
Existing neuroprotective drugs, such as MK-801, are limited in clinical application due to interference with normal neurophysiological functions. There is a lack of compounds that can precisely intervene in the overactivation of NMDA receptors under pathological conditions.
Using N-[(6-methoxy-1H-benzimidazol-2-yl)methyl]-3-(pyridin-3-yl)propionamide as a propionamide derivative, a dose-dependent neuroprotective effect is exerted by inhibiting the overactivation of N-methyl-D-aspartate receptors.
This propionamide derivative showed neuroprotective efficacy comparable to the positive control drug MK-801 in the treatment of glutamate excitotoxicity-mediated diseases such as ischemic stroke, Parkinson's disease, and Alzheimer's disease, with a dose-dependent increase in cell survival.
Smart Images
Figure CN121846092B_ABST